2023 World Conference on Lung Cancer (Posters)-P2.09. Treatment Adherence Disparities and Clinical Outcomes of Osimertinib among Ethnic-Minority Patients with EGFR-Mutated NSCLC

P2.09. Treatment Adherence Disparities and Clinical Outcomes of Osimertinib among Ethnic-Minority Patients with EGFR-Mutated NSCLC - PDF(Slides)

Back to course

Pdf Summary

This study examined treatment adherence disparities and clinical outcomes of Osimertinib, a targeted therapy for non-small cell lung cancer (NSCLC), among ethnic-minority patients with EGFR-mutated NSCLC. The researchers conducted a retrospective cohort study of 100 patients who were prescribed Osimertinib from 2016 to 2022. Adherence to the medication was measured using two methods: medication possession ratio (MPR) and proportion of days covered (PDC). The primary endpoint was overall survival (OS), and secondary endpoints included progression-free survival (PFS) and treatment duration.<br /><br />The results showed that there were no significant differences in adherence rates between different racial/ethnic groups. However, non-adherence to Osimertinib was associated with a higher risk of death based on the PDC measurement. It was also found that Hispanic patients had a higher risk of mortality compared to non-Hispanic White patients. Additionally, non-Hispanic Black patients had a higher risk of mortality compared to non-Hispanic White and non-Black patients. Squamous cell histology was associated with a decreased risk of mortality compared to adenocarcinoma histology.<br /><br />The study highlights potential survival disparities among ethnic-minority patients and those with lower incomes who are treated with Osimertinib. It suggests that further research is needed to optimize the usage of Osimertinib and improve clinical outcomes, particularly in real-world settings and with more diverse patient populations. The study also mentions an ongoing prospective study on the pharmacogenetics and metabolism of Osimertinib as part of this research.<br /><br />In conclusion, this study found that there were no significant differences in adherence rates to Osimertinib among different racial/ethnic groups. However, non-adherence was associated with a higher risk of death. The study suggests the need for further research and inclusion of a more diverse patient population to validate these findings and optimize Osimertinib usage and clinical outcomes.

Asset Subtitle

Matthew Lee

Meta Tag

Speaker Matthew Lee

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

treatment adherence

clinical outcomes

Osimertinib

NSCLC

ethnic-minority patients

adherence rates

mortality risk

diverse patient populations

survival disparities

pharmacogenetics